D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $21.00 price objective on the stock.

Several other research firms also recently issued reports on TRVI. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a research report on Tuesday, October 22nd. Raymond James assumed coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set an “outperform” rating and a $9.00 target price for the company. Leerink Partners started coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Trevi Therapeutics has an average rating of “Buy” and an average price target of $9.13.

Trevi Therapeutics Stock Down 2.8 %

Shares of NASDAQ TRVI opened at $2.78 on Wednesday. Trevi Therapeutics has a 12-month low of $1.00 and a 12-month high of $4.00. The firm has a market cap of $213.70 million, a PE ratio of -6.32 and a beta of 0.96. The company’s fifty day simple moving average is $3.02 and its 200 day simple moving average is $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the company earned ($0.08) earnings per share. On average, equities analysts predict that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Trevi Therapeutics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after acquiring an additional 60,249 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Trevi Therapeutics in the first quarter worth about $47,000. Rosalind Advisors Inc. boosted its stake in Trevi Therapeutics by 50.3% during the second quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after buying an additional 465,561 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Trevi Therapeutics by 38.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock valued at $532,000 after acquiring an additional 49,884 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Trevi Therapeutics by 44.8% during the 2nd quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock valued at $224,000 after acquiring an additional 23,263 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.